Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) Post author: Post published:August 23, 2026 Post category: Continue ReadingPhase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)
A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis Post author: Post published:August 23, 2026 Post category: Continue ReadingA Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis
A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease Post author: Post published:August 23, 2026 Post category: Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease
Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome Post author: Post published:August 23, 2026 Post category: Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published:August 23, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published:August 23, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease Post author: Post published:August 23, 2026 Post category: Continue ReadingPhase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A Post author: Post published:August 23, 2026 Post category: Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A
A Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach Post author: Post published:August 23, 2026 Post category: Continue ReadingA Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 Post author: Post published:August 23, 2026 Post category: Continue ReadingA Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1
